

Special Issue

Tumor Microenvironment and Anti-angiogenic Therapies

Message from the Guest Editors

Anti-angiogenic therapies should have revolutionized anti-tumoral strategies, but patient benefit is not the expected one. The aim of this Special Issue is to cover recent advances on the molecular and cellular mechanisms involved in tumor angiogenesis with a focus on major components of the tumor microenvironment, such as cancer associated fibroblasts, immune cells and endothelial cells progenitors and their close relation with the extracellular matrix. This special issue will also collect novel findings and reviews on the strategies aiming to control the stromal reaction of the tumor in the frame of anti-angiogenic and combinatorial treatments and the developments in the fields of tumor vessels and endothelial cell metabolism normalization that could open promising avenues to counter resistance mechanisms.

Guest Editors

Dr. Jerome Devy

Matrice Extracellulaire et Dynamique Cellulaire, MEDyC, UMR 7369 CNRS-URCA, Université de Reims Champagne-Ardenne, 51687 Reims CEDEX 2, France

Dr. Benoit Langlois

Matrice Extracellulaire et Dynamique Cellulaire, MEDyC, UMR 7369 CNRS-URCA, Université de Reims Champagne-Ardenne, 51687 Reims CEDEX 2, France

Deadline for manuscript submissions

closed (31 January 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/86783

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).